DB05687InvestigationalSmall molecule
BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).
- Mechanism
- Curator reviewed
In radioligand binding studies, BL-1020 displayed strong interaction with dopamine receptors especially D2L and D2S (Ki of 0.27 nM and 0.17 nM respectively), the serotonin receptor 5-HY2a (Ki 0.25 nM) as well as moderate interaction with the GABAA receptor (Ki 3.29 microK).
- Primary indication
- Investigated for use/treatment in schizophrenia and schizoaffective disorders.Curator reviewed
- Code names
- BL-1020
Resolves to
Compound
Targets
What you can answer from here — as of April 02, 2025
Which drugs share a target with BL-1020, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account